Citations

Clear

5486 citation(s) found for "Yu, Stephen".

O1‐10‐01: Clinical outcomes for stages of NIA‐AA preclinical Alzheimer's disease
Wiste, Heather J. , Weigand, Stephen D. , Lowe, Val J. , Ivnik, Robert J., Roberts, Rosebud O., Petersen, Ronald C. , Knopman, David S. , Jack, Clifford R. , Vemuri, Prashanthi , Kantarci, Kejal , Boeve, Bradley F. , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2012.05.257 Get It

P2‐075: Biomarker correlates in the ADNI Alzheimer's disease dementia population suggesting dementia unlikely due to Alzheimer's
Lowe, Val J. , Peller, Patrick J., Weigand, Stephen D. , Wiste, Heather J. , Senjem, Matthew L. , Petersen, Ronald C. , Jack, Clifford R. , Kantarci, Kejal , Vemuri, Prashanthi , Knopman, David S. , Boeve, Bradley F. , Senjem, Matthew L

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_8 | Pages: No page available

10.1016/j.jalz.2012.05.779 Get It

O3‐12‐04: Rates of PIB accumulation do plateau
Wiste, Heather J. , Weigand, Stephen D. , Lowe, Val J. , Lesnick, Timothy G. , Senjem, Matthew L. , Gunter, Jeffrey L. , Petersen, R.G., Jack, Clifford R. , Vemuri, Prashanthi , Knopman, David S. , Pankratz, V. Shane , Boeve, Bradley F. , Senjem, Matthew L

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_12 | Pages: No page available

10.1016/j.jalz.2012.05.1209 Get It

O4‐04‐04: NIA‐AA MCI criteria applied to the Mayo Clinic Study of Aging
Petersen, Ronald, Wiste, Heather J. , Weigand, Stephen D. , Lowe, Val J. , Gunter, Jeffrey L. , Ivnik, Robert J., Boeve, Bradley, Roberts, Rosebud O., Knopman, David S. , Jack, Clifford R. , Vemuri, Prashanthi , Kantarci, Kejal , Senjem, Matthew L. , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2012.05.1655 Get It

Trends in Minimally Invasive Surgery for the Kidney and Prostate—When are You Doing the Patient a Disservice by Not Referring?
Boorjian, Stephen A.

Mayo Clinic

Journal of Urology | July 19, 2012 | Volume: 188 | Issue: 3 | Pages: 702-703

10.1016/j.juro.2012.06.048 | PMID 22818348 Get It

Abstract 1038: Regulation of cyclin A by FoxO3a drives proliferation in anaplastic thyroid carcinoma
Rohl, Stephen D., Störz, Peter , Smallridge, Robert C., Copland, John A. , Marlow, Laura A. , Roemeling, Christina A. Von , Zhang, Yilin , Cooper, Simon JR , Tun, Han W.

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 1038-1038

10.1158/1538-7445.am2011-1038 Get It

Abstract The Forkhead transcription factor, FoxO3a, is a known suppressor of primary tumor growth and is negatively regulated by growth factors via phosphorylation and mislocalization from the nucleus to the cytoplasm. Here we show for the first time that FoxO3a is nuclear in anaplastic thyroid carcinoma (ATC) and it transcriptionally upregulates cyclin A thereby promoting tumor growth in human ATC cells. Silencing FoxO3a in ATC cell lines leads to down-regulation of cyclin A mRNA and protein while over-expression of FoxO3a leads to upregulation of cyclin A protein. Transient co-transfection of cyclin A promoter linked to luciferase with FoxO3a leads to enhanced luciferase activity, which can be ablated when mutating the FoxO3a site on the cyclin A promoter. This combined data implicates an entirely novel function for FoxO3a in modulating cancer progression by promoting cell cycle progression and tumor growth. ATC is a poorly differentiated carcinoma with average survival upon diagnosis of 3–4 months with 99% lethality, notably the most aggressive and deadliest cancers known. This data also suggest that any therapies under development to inactivate FOXO3a may be effective at blocking tumor expansion. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1038. doi:10.1158/1538-7445.AM2011-1038
Abstract 2994: Constitutional telomere length correlates with colorectal cancer (CRC), but varies by age of cancer onset
Boardman, Lisa A., Johnson, Ruth, Thibodeau, Stephen N. , Petersen, Gloria M. , Cunningham, Julie M. , Boardman, Lisa A., Skinner, Halcyon G. , Seo, Songwon , Gangnon, Ronald E. , Litzelman, Kristin , Engelman, Corinne D.

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 2994-2994

10.1158/1538-7445.am2011-2994 Get It

Abstract Introduction: Short constitutional telomere length is associated with aging and cancer, but the correlation of telomere length and age at diagnosis of CRC has not been evaluated. Methods: We measured telomere length using quantitative PCR of peripheral blood leukocyte DNA in 1026 individuals diagnosed with MSS CRC who were ≤60 years of age and were chemo-radiotherapy naïve at the time of blood draw. We compared telomere length with 1972 unrelated healthy controls who were frequency matched for gender and age at time of blood collection. We used constructed percentiles of telomere length using the data from the controls. Results: Overall, regardless of cancer status, there was a weak negative correlation of telomere length with age such that as age increased telomere length decreased (Pearson correlation coefficient =−0.1, p< 0.0001); and men had shorter telomeres than women (p=0.0002). The odds ratio (OR) for MSS CRC increased with longer telomere length (OR 1.62 [CI: 1.31-1.99] for those with telomere lengths in the 90th percentile compared to those with telomere lengths in the 50th percentile. In multivariate analysis with adjustment for gender, BMI, smoking, alcohol, and diabetes, telomere length remained an independent risk factor for CRC (p< 0.001), with interaction between telomere length and age (≤50, longer telomeres increased CRC risk; > 50 years old, increasing telomere length associated with decreased CRC risk). Risk was higher for MSS CRC ≤50 years for patients with telomere lengths in the 90th percentile compared to those in the 50th percentile (OR 2.31; CI:1.65-3.23). For subjects diagnosed 50-60 yrs, longer telomere length was associated with lower risk of CRC, and shorter telomere length was associated with the development of CRC (OR 1.22 for telomere lengths in the 10th percentile compared to those in the 50th percentile (OR 1.22:CI; 1.05-1.43). Conclusion: Telomere dynamics appear to influence MSS CRC risk and may differ on the basis of age of cancer diagnosis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2994. doi:10.1158/1538-7445.AM2011-2994
Abstract 2761: A two-stage evaluation of genetic variation in immune and inflammation genes and risk of non-Hodgkin lymphoma (NHL)
Fredericksen, Zachary S., Novak, Anne J. , Ansell, Stephen M. , Liebow, Mark , Cunningham, Julie M. , Wang, Alice H., Cerhan, James R. , Kay, Neil E. , Doǧan, Ahmet , Witzig, Thomas E. , Habermann, Thomas M. , Slager, Susan L.

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 2761-2761

10.1158/1538-7445.am2011-2761 Get It

Abstract Background: NHL is a malignancy of lymphocytes, and there is growing evidence for a role of immune dysfunction in the etiology of this malignancy. We conducted a 2-stage analysis of single nucleotide polymorphisms (SNPs) from 1,253 genes using the ParAllele (now Affymetrix) Immune and Inflammation Panel with risk of NHL. Methods: In Stage 1, we successfully genotyped 7,670 SNPs in a clinic-based study of 425 NHL cases and 465 frequency matched controls seen at the Mayo Clinic. Genes were tagged with SNPs from HapMap to provide coverage at r2 = 0.8 and minor allele frequency (MAF) >0.05. In Stage 2, we genotyped the top 768 SNPs on an additional 584 cases and 768 controls from the Mayo Clinic Study, and then conducted a pooled analysis of all 1009 cases and 1233 controls. The association of individual SNPs with NHL risk was assessed using the Odds Ratios (ORs) and 95% confidence intervals, adjusted for age and gender. The most prevalent homozygous genotype was used as the reference group, and each SNP was modeled individually as having a log-additive effect. Results: Overall, the mean age at diagnosis was 62.0 years for cases and the mean age at enrollment for controls was 61.1 years. The most common subtypes were chronic lymphocytic leukemia (CLL, N=343), follicular lymphoma (FL, N=245), and diffuse large B-cell lymphoma (DLBCL, N=178). In the pooled analysis, there were 3 SNPs at p<0.0004. The top SNP was rs241447 (MAF=0.26) from TAP2 at 6p21.3 (OR=1.34, 95% CI 1.17-1.53, p=0.00003). This SNP is a cSNP that leads to a missense change (Ala→Thr). The second SNP was rs2857597 (MAF=0.26) from AIF1, also at 6p21.3 (OR=0.77, 95% CI 0.67-0.88, p=0.0002). The region spanning these two SNPs had multiple risk SNPs with p<0.01, including SNPs in BAT2 (rs3132453), BAT3 (rs2242656), C2 (rs7746553), HLA-DRA (rs8084, rs7192), and TAP2 (rs1894408). Of these SNPs, only rs241447 (TAP2) and rs7192 (HLA-DRA) displayed any substantial LD (r2=0.84, all other r2<0.25). The third SNP was rs754505 (MAF=0.07) from NFATC1 at 18q23 (OR=0.63, 95% CI 0.49-0.81, p=0.0003). There were 4 additional SNPs in this gene with a p<0.05 (rs7240932, rs396127, rs177820, rs183374). In subtype analysis, the SNPs from 6p21.3 showed the strongest associations with FL (including the TAP2 SNP rs241447, p=6.9 × 10−8), although there were also associations with CLL (except for the TAP2 and C2 SNPs) and DLBCL (except for the HLA-DRA SNPs). For NFATC1 the associations were similar across the main NHL subtypes. Conclusions: We identified strong associations with NHL risk in the 6p21.3 region, which includes the MHC locus. Our results were particularly striking for FL and supports recent GWAS and candidate gene studies that implicate this region. We also identified NFATC1 as a susceptibility gene. NFATC1 is known to regulate the expression of growth and survival genes including MYC, TNF, CD40L, and BAFF, all of which have also been linked to lymphomagenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2761. doi:10.1158/1538-7445.AM2011-2761
Abstract 2742: Assessment of next generation platforms and use of duplicate runs for whole exome sequencing
DeRycke, Melissa S. , Gunawardena, Shanaka R., Eckloff, Bruce W., Asmann, Yan W. , Schaid, Daniel J. , Goode, Ellen L. , Thibodeau, Stephen N. , Middha, Sumit , McDonnell, Shannon K.

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 2742-2742

10.1158/1538-7445.am2011-2742 Get It

Abstract Several platforms for genome sequencing and methods for exon enrichment are now available and continue to evolve quickly. In this study, we compared the performance of whole exome sequencing using two instruments, Illumina's GAIIx and HiSeq 2000, comparing single versus duplicate runs. Eight runs of eight samples each were performed with genomic DNA derived from whole blood and sample libraries prepared with the Agilent SureSelect capture array. One run was conducted in duplicate on the GAIIx, and, for some analyses, the combined data were used. We used TREAT (Targeted RE-sequencing and Annotation Tool), developed in-house for data analysis, including sequence alignment (MAQ, BWA), local re-alignment (GATK), variant calling (utilizing MAQ), annotation (SIFT and Seattle Seq), and visualization. Overall, duplicate runs on the GAIIx platform (compared to a single run) increased the number of total reads by approximately two-fold: from ∼66 M to ∼130 M. For both single and duplicate runs, ∼90% of reads mapped to the reference sequence, and ∼55% of reads mapped on-target. Of importance, the percent coverage of the target region increased substantially with duplicate runs; ∼72% of the target region was covered at 40-fold or more when run in duplicate compared to only ∼52% when run once. At 30x, 20x, and 10x, there was a 1.3- (62% v. 78%), 1.2- (72% v. 84%), and 1.1-fold (84% v. 91%) increase respectively, in the percent coverage of the target region for samples run twice. A similar number of filtered, on-target SNPs per sample (∼24 K) was found for both single and duplicate run analyses. However, a 1.3-fold increase in the number of on-target indels was seen in the duplicate run (∼1,200) compared to the single run (∼900). When the combined data for samples run twice on a GAIIx were compared to the samples run using a HiSeq, the total number of reads were similar (∼130 M), although several of the samples had substantially more reads on the HiSeq platform. Samples run on a HiSeq had an increase in the percent coverage of the target region at 40x (72% v. 81%), 30x (78% v. 86%), 20x (84% v. 91%) and 10x (91% v. 95%) compared to the two-run approach on a GAIIx. A similar number of filtered on-target SNPs (∼24 K/sample) and indels (∼1200) was found with the HiSeq compared to two runs on a GAIIx. In summary, our results demonstrate increases in the total number of reads and in overall coverage with the HiSeq 2000 instrument. The total number of SNPs and indel that mapped on target for the version 1 Agilent SureSelect capture array is ∼25 K and 1,200 per sample, respectively. As capture is of variable efficiency for individual runs, higher average coverage of the target region is necessary for sufficient coverage of poorly captured regions. Additional analyses comparing Agilent SureSelect versions 1 and 2 arrays are underway. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2742. doi:10.1158/1538-7445.AM2011-2742